Shares of Hortonworks, Inc. (HDP) surged more than 10% in after-hours trading Wednesday as the company reported better-than-expected financial results. HDP's quarterly performance was highlighted by support subscription revenue growth of 178% year-over-year and solid customer momentum with the addition of 119 new support subscription logos.
For the second quarter 2015, HDP posted revenue of $30.7 million, a 154% increase year over year, and non-GAAP net loss of ($34.1) million or ($0.80) per diluted share, topping the Capital IQ Consensus Estimate of ($0.84) loss per share on revenues of $23.28 million for the period.
For the full year 2015, HDP expects revenue to be in a range of $114.0 million to $117.0 million, representing year-over-year growth of 122% at the midpoint and surpassing the Capital IQ Consensus Estimate of $97.41 million in revenue for the period
HDP develops, distributes and supports the only 100% open source Apache Hadoop data platform.
More about Hortonworks, Inc. (HDP) at www.hortonworks.com
**
Despite the challenging market conditions, Transocean Ltd. (RIG) delivered quarterly financial results well above Wall Street analysts’ expectations
For the second quarter 2015, RIG posted revenues of $1.884 billion and adjusted (excluding non-recurring items) net income of $408 million, $1.11 per diluted share, exceeding the Capital IQ Consensus Estimate of $0.51 earnings per share on revenues of $1.71 billion for the period
RIG said that it delivered strong operating results and underlying cash flow in the period due to exceptional revenue efficiency and a relentless emphasis on cost management.
RIG is a leading international provider of offshore contract drilling services for oil and gas wells.
More about Transocean Ltd. (RIG) at www.deepwater.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company has added 184 countries, 56 dependent territories and their respective cities or communities into its CRWE WORLD ( www.crweworld.com ), a community specific news, information and engagement platform. CRWE WORLD primary goal is to become a one-stop shop for the various needs of online consumers ranging from Real Estate, Coupons & Deals, Business Directory and much more, while providing news and information.
The CRWE WORLD network will give people access to local, national and international news while also allowing them to post community-specific content related with their location. With the CRWE WORLD network, visitors will be able to change its location to other communities globally to discover information in reference to the location selected.
The CRWE WORLD network will provide businesses a tool to target its marketing message locally, nationally and internationally, as well as targeting potential consumers in a specific location, such as within a certain zip code
CRWE WORLD’s Business Plan: http://crownequityholdings.com/Business_Plan.html
CRWE's Curbiz ( www.curbiz.com ), in development stage, is an online business directory connecting people with local, state, country and global businesses. Curbiz will provide local advertising services, including free and paid business listing services to businesses of various sizes, as well as enable businesses to deliver targeted search advertising to large local audiences through its Website and partnership with the CRWE WORLD Network.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Keep a close eye on GW Pharmaceuticals plc (GWPH). The company will announce its third quarter fiscal 2015 financial results on Thursday (August 6) before the market opens.
GWPH recently commenced the second of two Phase 3 clinical trials of Epidiolex(R) (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. The company anticipates that top-line data from this trial will be available in the first quarter of 2016.
GWPH is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
GWPH commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GWPH is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R), which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex.
GWPH has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia.
More about GW Pharmaceuticals plc (GWPH) at www.gwpharm.com.
**
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer
For the second quarter 2015, HDP posted revenue of $30.7 million, a 154% increase year over year, and non-GAAP net loss of ($34.1) million or ($0.80) per diluted share, topping the Capital IQ Consensus Estimate of ($0.84) loss per share on revenues of $23.28 million for the period.
For the full year 2015, HDP expects revenue to be in a range of $114.0 million to $117.0 million, representing year-over-year growth of 122% at the midpoint and surpassing the Capital IQ Consensus Estimate of $97.41 million in revenue for the period
HDP develops, distributes and supports the only 100% open source Apache Hadoop data platform.
More about Hortonworks, Inc. (HDP) at www.hortonworks.com
**
Despite the challenging market conditions, Transocean Ltd. (RIG) delivered quarterly financial results well above Wall Street analysts’ expectations
For the second quarter 2015, RIG posted revenues of $1.884 billion and adjusted (excluding non-recurring items) net income of $408 million, $1.11 per diluted share, exceeding the Capital IQ Consensus Estimate of $0.51 earnings per share on revenues of $1.71 billion for the period
RIG said that it delivered strong operating results and underlying cash flow in the period due to exceptional revenue efficiency and a relentless emphasis on cost management.
RIG is a leading international provider of offshore contract drilling services for oil and gas wells.
More about Transocean Ltd. (RIG) at www.deepwater.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company has added 184 countries, 56 dependent territories and their respective cities or communities into its CRWE WORLD ( www.crweworld.com ), a community specific news, information and engagement platform. CRWE WORLD primary goal is to become a one-stop shop for the various needs of online consumers ranging from Real Estate, Coupons & Deals, Business Directory and much more, while providing news and information.
The CRWE WORLD network will give people access to local, national and international news while also allowing them to post community-specific content related with their location. With the CRWE WORLD network, visitors will be able to change its location to other communities globally to discover information in reference to the location selected.
The CRWE WORLD network will provide businesses a tool to target its marketing message locally, nationally and internationally, as well as targeting potential consumers in a specific location, such as within a certain zip code
CRWE WORLD’s Business Plan: http://crownequityholdings.com/Business_Plan.html
CRWE's Curbiz ( www.curbiz.com ), in development stage, is an online business directory connecting people with local, state, country and global businesses. Curbiz will provide local advertising services, including free and paid business listing services to businesses of various sizes, as well as enable businesses to deliver targeted search advertising to large local audiences through its Website and partnership with the CRWE WORLD Network.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Keep a close eye on GW Pharmaceuticals plc (GWPH). The company will announce its third quarter fiscal 2015 financial results on Thursday (August 6) before the market opens.
GWPH recently commenced the second of two Phase 3 clinical trials of Epidiolex(R) (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. The company anticipates that top-line data from this trial will be available in the first quarter of 2016.
GWPH is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
GWPH commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GWPH is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R), which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex.
GWPH has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia.
More about GW Pharmaceuticals plc (GWPH) at www.gwpharm.com.
**
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer
